Yahoo Malaysia Web Search

Sign In

Search results

  1. www.marketscreener.com › quote › stockUnity Biotechnology, Inc. Stock - MarketScreener.com

    6 days ago · Unity Biotechnology, Inc. is a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging. The Company is focused on creating medicines to selectively eliminate or modulate senescent cells and thereby provide transformative benefit in age-related ophthalmologic and neurologic diseases.

  2. ir.unitybiotechnology.com › stock-information › stock-chartStock Quote & Chart | Unity Biotechnology

    6 days ago · The Investor Relations website contains information about Unity Biotechnology's business for stockholders, potential investors, and financial analysts.

  3. simplywall.st › nasdaq-ubx › unity-biotechnologyUnity Biotechnology NasdaqGS:UBX Stock Report - Simply Wall St

    4 days ago · Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company’s lead drug candidate includes UBX1325, which is Phase 2 clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular ...

  4. markets.ft.com › data › equitiesUNITY Biotechnology Inc, UBX:NSQ summary - FT.com

    5 days ago · Unity Biotechnology, Inc. is a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging. The Company is focused on creating medicines to selectively eliminate or modulate senescent cells and t hereby provide transformative benefit in age-related ophthalmologic and neurologic diseases.

  5. www.wallstreetzen.com › stocks › usUnity Biotechnology Stock Price Today (NASDAQ: UBX) Quote, Market...

    Jun 15, 2024 · Unity Biotechnology stock was originally listed at a price of $166.50 in May 3, 2018. If you had invested in Unity Biotechnology stock at $166.50, your return over the last 6 years would have been -99.14%, for an annualized return of -54.75% (not including any dividends or dividend reinvestments).

  6. synapse.patsnap.com › article › unity-biotechnology-inc-q1UNITY Biotechnology, Inc. Q1 2024 Financial Results and Business...

    4 days ago · May 14, 2024 -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology firm specializing in therapies to address age-related diseases, has released its financial report for the first quarter ending March 31, 2024. Anirvan Ghosh, Ph.D., UNITY's CEO, commented on the company's ongoing efforts in the Phase 2b ASPIRE study, which ...

  7. www.pharmaceutical-technology.com › data-insightsRisk adjusted net present value: What is the current valuation of...

    6 days ago · Unity Biotechnology’s product portfolio includes UBX0101, intended for musculoskeletal diseases; and UBX1325, for age-related diseases, including diabetic retinopathy and diabetic macular edema, glaucoma and age-related macular degeneration. It involves in developing products for idiopathic pulmonary fibrosis, systemic sclerosis, chronic ...